LAMPIRE’s Llama Monoclonal vHH nanobody platform streamlines antibody discovery using single-cell sorting of target-positive llama and alpaca B cells. This approach delivers vHH sequences within three weeks, reduces costs by eliminating library creation and duplicate clones, and captures the full antibody repertoire for insight into clonotype, affinity, and epitope. For therapeutics, in silico assessments of developability, human-ness, and immunogenicity guide candidate selection, with optional sequence liability removal and humanization to accelerate discovery.